Home » Stocks » DRNA

Dicerna Pharmaceuticals, Inc. (DRNA)

Stock Price: $24.76 USD -0.51 (-2.02%)
Updated December 1, 4:00 PM EST - Market closed

Stock Price Chart

Key Info

Market Cap 1.86B
Revenue (ttm) 130.43M
Net Income (ttm) -115.83M
Shares Out 75.04M
EPS (ttm) -1.60
PE Ratio n/a
Forward PE 28.49
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 1
Last Price $24.76
Previous Close $25.27
Change ($) -0.51
Change (%) -2.02%
Day's Open 25.14
Day's Range 24.71 - 25.65
Day's Volume 627,089
52-Week Range 13.37 - 26.91

More Stats

Market Cap 1.86B
Enterprise Value 1.27B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 75.04M
Float n/a
EPS (basic) -1.61
EPS (diluted) -1.60
FCF / Share 2.67
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield 10.71%
Payout Ratio n/a
Shares Short 5.77M
Short Ratio 9.32
Short % of Float n/a
Beta 1.37
PE Ratio n/a
Forward PE 28.49
P/FCF Ratio 9.34
PS Ratio 14.25
PB Ratio 11.41
Revenue 130.43M
Operating Income -122.92M
Net Income -115.83M
Free Cash Flow 198.96M
Net Cash 588.33M
Net Cash / Share 7.84
Gross Margin -65.50%
Operating Margin -94.24%
Profit Margin -88.80%
FCF Margin 152.54%
ROA -15.09%
ROE -80.42%
ROIC -42.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (11)

Buy 10
Overweight 1
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$35.00*
(41.36% upside)
Low
25.0
Current: $24.76
High
45.0
Target: 35.00
*Average 12-month price target from 9 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014201320122011
Revenue23.906.181.03-0.18--7.027.91
Revenue Growth287.05%499.61%------11.29%-
Gross Profit23.906.181.03-0.18--7.027.91
Operating Income-128-90.35-60.74-59.75-63.03-45.10-17.38-9.25-7.61
Net Income-120-88.85-60.20-59.51-62.84-47.94-18.52-10.12-8.56
Shares Outstanding68.4355.6221.9220.7220.3216.070.030.030.03
Earnings Per Share-1.76-1.60-3.66-2.87-3.09-3.00-709.57-516.00-492.76
Operating Cash Flow-0.6918.30-45.33-48.75-48.80-34.76-10.94-15.74-8.87
Capital Expenditures-6.35-0.36-0.13-0.45-1.13-2.01-0.41-0.12-0.50
Free Cash Flow-7.0417.94-45.46-49.20-49.93-36.78-11.36-15.86-9.37
Cash & Equivalents34930311445.8794.6196.1246.603.6722.49
Total Debt20.14-----4.858.8011.57
Net Cash / Debt32930311445.8794.6196.1241.75-5.1310.92
Assets59740912151.2510010449.7910.1924.64
Liabilities44520819.9210.049.005.278.4710.6615.12
Book Value15220110141.2191.0298.34-68.92-64.72-50.63
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Dicerna Pharmaceuticals, Inc.
Country United States
Employees 187
CEO Douglas M. Fambrough

Stock Information

Ticker Symbol DRNA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: DRNA
IPO Date January 30, 2014

Description

Dicerna Pharmaceuticals, a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiometabolic diseases. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; and a program for an undisclosed rare liver disease. The company's development programs also comprise DCR-A1AT programs; and a program for the treatment of neurodegeneration and pain. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, Roche, Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was founded in 2006 and is headquartered in Lexington, Massachusetts.